Mohammad Nadeem Khan¹* and Praveen Chandra Dubey²

¹Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College and PG Institute, Sri Aurobindo University, Indore, Madhya Pradesh, India
²Chairman SEAC, Government of Madhya Pradesh Bhopal Madhya Pradesh, India

*Corresponding Author: Mohammad Nadeem Khan, Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College and PG Institute, Sri Aurobindo University, Indore, Madhya Pradesh, India.

Received: February 28, 2024; Published: March 10, 2024

Abstract

The rising global prevalence of obesity has led to increased research interest in novel strategies for its management. This review explores the potential role of nutraceuticals in mitigating obesity's metabolic consequences at the molecular level. Nutraceuticals, bioactive compounds derived from food, have shown promise in modulating various pathways associated with obesity, including inflammation, lipid metabolism, and insulin sensitivity. The metabolic consequences of obesity encompass a spectrum of disturbances, including insulin resistance, chronic inflammation, dyslipidemia, and oxidative stress. Nutraceuticals offer a unique approach by targeting these pathways at the molecular level. For instance, green tea extract containing epigallocatechin gallate (EGCG) has demonstrated potential in enhancing fat oxidation and metabolic rate. Omega-3 fatty acids from fish oil exhibit anti-inflammatory effects, addressing one of the key metabolic consequences of obesity. Formulating stable and high-quality supplements is paramount to ensuring consistent efficacy. Moreover, a personalized approach considering individual variations in response to nutraceuticals may enhance outcomes. Identifying specific strains of probiotics with proven efficacy in modulating gut microbiota, a key player in metabolic health, is crucial. Additionally, combinations of nutraceuticals that target multiple pathways simultaneously may have synergistic effects, providing a comprehensive approach to reducing the metabolic consequences of obesity. It is essential to emphasize that nutraceuticals should be viewed as complementary to lifestyle interventions, including a balanced diet and regular physical activity. Further research and clinical studies are warranted to validate the efficacy and safety of nutraceutical interventions, paving the way for more targeted and personalized approaches to obesity management.

Keywords: Functional Foods; Bioactive Compounds; Weight Management; Obesity; Metabolic Consequences; Thermogenesis; Appetite Regulation; Fat Metabolism; Blood Glucose; Inflammation; Gut Microbiota; Antioxidants; Hormonal Regulation

References

1. Flegal KM., et al. “Prevalence and trends in obesity among US adults, 1999-2008”. JAMA 303 (2010): 235-241.
2. Nguyen DM and El-Serag HB. “The epidemiology of obesity”. Gastroenterology Clinics of North America 39 (2010): 17.
3. Grimm ER and Steinle NI. “Genetics of eating behavior: established and emerging concepts”. Nutrition Reviews 69 (2011): 52-60.
4. Lake A and Townshend T. “Obesogenic environments: exploring the built and food environments”. Journal of the Royal Society for the Promotion of Health 126 (2006): 262-267.
5. Booth KM., et al. “Obesity and the built environment”. Journal of the American Dietetic Association 105 (2010): S110-S117.
6. Davis MA., et al. “Health behaviors and utilization among users of complementary and alternative medicine for treatment versus health promotion”. Health Services Research (2011).
7. Nahin RL., et al. “Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007”. National Health Statistics Reports 18 (2009): 1-14.
8. Eisenberg DM., et al. “Unconventional medicine in the United States: prevalence, costs, and patterns of use”. The New England Journal of Medicine 328 (1993): 246-252.
9. Saper RB., et al. “Common dietary supplements for weight loss”. American Family Physician 70 (2004): 1731-1738.
10. Blanck HM., et al. “Use of nonprescription dietary supplements for weight loss is common among Americans”. Journal of the American Dietetic Association 107 (2007): 441-447.
11. Bertisch SM., et al. “Use of complementary and alternative therapies by overweight and obese adults”. Obesity 16 (2008): 1610-1615.
12. Pillitteri JL., et al. “Use of dietary supplements for weight loss in the United States: results of a national survey”. Obesity 16 (2008): 790-796.
13. Slavin JL. “Position of the American Dietetic Association: health implications of dietary fiber”. Journal of the American Dietetic Association 10 (2008): 1716-1731.
14. O’Neil CE., et al. “Whole-grain consumption is associated with diet quality and nutrient intake in adults: the National Health and Nutrition Examination Survey, 1999-2004”. Journal of the American Dietetic Association 110 (2010): 1461-1468.
15. Nicklas TA., et al. “Dietary fiber intake of children and young adults: the Bogalusa Heart Study”. Journal of the American Dietetic Association 95 (1955): 209-214.
16. Ello-Martin JA., et al. “Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets”. The American Journal of Clinical Nutrition 85 (2007): 1465-1477.
17. Ledikwe JH., et al. “Dietary energy density is associated with energy intake and weight status in US adults”. The American Journal of Clinical Nutrition 83 (2006): 1362-1368.
18. Kant AK and Graubard BI. “Energy density of diets reported by American adults: association with food group intake, nutrient intake, and body weight”. International Journal of Obesity (London) 8 (2005): 950-956.
19. Ledikwe JH., et al. “Low-energy-density diets are associated with high diet quality in adults in the United States”. Journal of the American Dietetic Association 106 (2006): 1172-1180.
20. Liu S., et al. “Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women”. The American Journal of Clinical Nutrition 78 (2003): 920-927.
21. Schiller RN., et al. “A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals”. Journal of the American Nutrition Association 4 (2001): 42-49.
22. Kaats GR., et al. “Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol”. Journal of the American College of Nutrition 25 (2006): 389-394.
23. Kovacs EM., et al. “The effect of addition of modified guar gum to a low-energy semisolid meal on appetite and body weight loss”. International Journal of Obesity and Related Metabolic Disorders 25 (2001): 307-315.
24. Evans E and Miller DS. “Bulking agents in the treatment of obesity”. Nutrition and Metabolism 18 (1975): 199-203.
25. Kovacs EM., et al. “The effect of guar gum addition to a semisolid meal on appetite related to blood glucose, in dieting men”. European Journal of Clinical Nutrition 56 (2002): 771-778.
26. Lyly M., et al. “Fibre in beverages can enhance perceived satiety”. European Journal of Nutrition 48 (2009): 251-258.
27. Pittler MH and Ernst E. “Guar gum for body weight reduction: metaanalysis of randomized trials”. The American Journal of Medicine 110 (2001): 724-730.
28. McCarty MF. “Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control”. Medical Hypotheses 42 (1994): 215-225.
29. Heymsfield SB., et al. “Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial”. JAMA 280 (1998): 1596-1600.
30. Vasques CA., et al. “Evaluation of the pharmacotherapeutic efficacy of Garcinia cambogia plus Amorphophallus konjac for the treatment of obesity”. Phytotherapy Research 22 (2008): 1135-1140.
31. Kovacs EM., et al. “Effects of 2-week ingestion of (–)-hydroxycitrate and (–)-hydroxycitrate combined with medium-chain triglycerides on satiety and food intake”. Physiology and Behavior 74 (2001): 543-549.
32. Preuss HG., et al. “Efficacy of a novel calcium/potassium salt of (–)-hydroxycitric acid in weight control”. International Journal of Clinical Pharmacology Research 25 (2005): 133-144.
33. Kriketos AD., et al. “(–)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state”. International Journal of Obesity and Related Metabolic Disorders 23 (1999): 867-873.
34. Lim K., et al. “(–)-Hydroxycitric acid ingestion increases fat utilization during exercise in untrained women”. Journal of Nutritional Science and Vitaminology (Tokyo) 49 (2003): 163-167.
35. Preuss HG., et al. “An overview of the safety and efficacy of a novel, natural (–)-hydroxycitric acid extract (HCA-SX) for weight management”. Journal of Medicine 35 (2004): 33-48.
36. Bhattacharya A., et al. “Biological effects of conjugated linoleic acids in health and disease”. The Journal of Nutritional Biochemistry 17 (2006): 789-810.
37. Plourde M., et al. “Conjugated linoleic acids: why the discrepancy between animal and human studies?” Nutrition Reviews 66 (2008): 415-421.
38. Kanaya N and Chen S. “Conjugated linoleic acid reduces body weight gain in ovariectomized female C57BL/6J mice”. Nutrition Research 30 (2010): 714-721.
39. Joseph SV., et al. “Trans-8, cis-10+ cis-9, trans11-conjugated linoleic acid mixture alters body composition in Syrian golden hamsters fed a hypercholesterolaemic diet”. British Journal of Nutrition 104 (2010): 1443-1449.
40. Wendel AA., et al. “Conjugated linoleic acid induces uncoupling protein 1 in white adipose tissue of ob/ob mice”. Lipids 44 (2009): 975-982.
41. Parra P., et al. “Moderate doses of conjugated linoleic acid isomers mix contribute to lowering body fat content maintaining insulin sensitivity and a noninflammatory pattern in adipose tissue in mice”. The Journal of Nutritional Biochemistry 21 (2010): 107-115.
42. Halade GV., et al. “Combination of conjugated linoleic acid with fish oil prevents age-associated bone marrow adiposity in C57Bl/6J mice”. The Journal of Nutritional Biochemistry 22 (2011): 459-469.
43. Larsen TM., et al. “Conjugated linoleic acid supplementation for 1 y does not prevent weight or body fat regain”. The American Journal of Clinical Nutrition 83 (2006): 606-612.
44. Malpuech-Brugère C., et al. “Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans”. Obesity Research 12 (2004): 591-598.
45. Venkatramanan S., et al. “Milk enriched with conjugated linoleic acid fails to alter blood lipids or body composition in moderately overweight, borderline hyperlipidemic individuals”. Journal of the American College of Nutrition 29 (2010): 152-159.
46. Whigham LD., et al. “Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans”. The American Journal of Clinical Nutrition 85 (2007): 1203-1211.
47. Gaullier JM., et al. “Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans”. The American Journal of Clinical Nutrition 79 (2004): 1118-1125.
48. Watras AC., et al. “The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain”. International Journal of Obesity (London) 31 (2007): 481-487.
49. Khan N and Mukhtar H. “Tea polyphenols for health promotion”. Life Science 81 (2007): 519-533.
50. Perva-Uzunalić A., et al. “Extraction of active ingredients from green tea (Camellia sinensis): extraction efficiency of major catechins and caffeine”. Food Chemistry 96 (2006): 597-605.
51. Cross SE., et al. “Green tea extract selectively targets nanomechanics of live metastatic cancer cells”. Nanotechnology 22 (2011): 215101.
52. Roy AM., et al. “Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation”. Molecular Cancer Therapeutics 4 (2005): 81-90.
53. Sadava D., et al. “The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells”. Biochemical and Biophysical Research Communications 360 (2007): 233-237.
54. Tran PL., et al. “Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo”. BMC Cancer 10 (2010): 276.
55. Ikeda I. “Multifunctional effects of green tea catechins on prevention of the metabolic syndrome”. Asia Pacific Journal of Clinical Nutrition 17 (2008): 273-274.
56. Wang H., et al. “Effects of catechin enriched green tea on body composition”. Obesity 18 (2010): 773-779.
57. Nagao T., et al. “A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes”. Obesity 17 (2009): 310-317.
58. Nagao T., et al. “A green tea extract high in catechins reduces body fat and cardiovascular risks in humans”. Obesity 15 (2007): 1473-1483.
59. Maki KC., et al. “Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults”. The Journal of Nutrition 139 (2009): 264-270.
60. Nagao T., et al. “Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men”. The American Journal of Clinical Nutrition 81 (2005): 122-129.
61. Rains TM., et al. “Antiobesity effects of green tea catechins: a mechanistic review”. The Journal of Nutritional Biochemistry 22 (2011): 1-7.
62. Lekehal M., et al. “Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes”. Hepatology 24 (1996): 212-218.
63. Luo XJ., et al. “Recent advances in the study on capsaicinoids and capsinoids”. European Journal of Pharmacology 650 (2011): 1-7.
64. Snitker S., et al. “Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications”. The American Journal of Clinical Nutrition 89 (2009): 45-50.
65. Josse AR., et al. “Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise”. Nutrition and Metabolism (Lond) 7 (2010): 65.
66. Westerterp-Plantenga MS., et al. “Sensory and gastrointestinal satiety effects of capsaicin on food intake”. International Journal of Obesity 29 (2005): 682-688.
67. Ludy Mj and Mattes RD. “The effects of hedonically acceptable red pepper doses on thermogenesis and appetite”. Physiology and Behavior 102 (2011): 251-258.
68. Belza A., et al. “Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects”. International Journal of Obesity (London) 31 (2007): 121-130.
69. Joo JI., et al. “Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet”. Journal of Proteome Research 9 (2010): 2977-2987.
70. Lee RA and Balick MJ. “Indigenous use of Hoodia gordonii and appetite suppression”. Explore (NY) 3 (2007): 404-406.
71. MacLean DB and Luo LG. “Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside”. Brain Research 1020 (2004): 111.

Citation

Citation: Mohammad Nadeem Khan and Praveen Chandra Dubey. “Nutraceuticals for Molecular level Obesity Management; A Review of Its Possible Role on Obesity’s Metabolic Consequences and Obesity Management".Acta Scientific Nutritional Health 8.3 (2024): 27-28.

Copyright

Copyright: © 2024 Mohammad Nadeem Khan and Praveen Chandra Dubey. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.